# Determinants of Diabetes Remission After Gastric Bypass Surgery

> **NCT02287285** · EARLY_PHASE1 · COMPLETED · sponsor: **Blandine Laferrere** · enrollment: 25 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Exendin9

## Key facts

- **NCT ID:** NCT02287285
- **Lead sponsor:** Blandine Laferrere
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-08
- **Final completion:** 2019-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287285, "Determinants of Diabetes Remission After Gastric Bypass Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02287285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*